Supplemental Tables S1-2 from A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma

Autor: Saskia A.G.M. Cillessen, Anne L. Lennard, Chris J.J. Mulder, Chris J.L.M. Meijer, Joost J. Oudejans, Otto J. Visser, Wieke H.M. Verbeek, Marijn Radersma, Michal K. Sieniawski, Jolanda M.W. van de Water, Johannes Berkhof, Laura R. de Baaij

Supplemental Tables S1-2. Supplementary Table S1 shows the phenotype of the included EATLs. Supplementary Table S2 demonstrates the development of the model by cross validation after applying the bootstrap method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226dad37388c12dae57f9907b0cd7ade
https://doi.org/10.1158/1078-0432.22457477.v1

Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Autor: Karlijn de Joode, Jolien Tol, Paul Hamberg, Marissa Cloos, Elisabeth A. Kastelijn, Jessica S.W. Borgers, Veerle J.A.A. Nuij, Yarne Klaver, Gerarda J.M. Herder, Pim G.N.J. Mutsaers, Daphne W. Dumoulin, Esther Oomen-de Hoop, Nico G.J. van Diemen, Eduard J. Libourel, Erica J. Geraedts, Gerben P. Bootsma, Cor H. van der Leest, Anne L. Peerdeman, Karin H. Herbschleb, Otto J. Visser, Haiko J. Bloemendal, Hanneke W.M. van Laarhoven, Elisabeth G.E. de Vries, Lizza E.L. Hendriks, Laurens V. Beerepoot, Hans M. Westgeest, Franchette W.P.J. van den Berkmortel, John B.A.G. Haanen, Anne-Marie C. Dingemans, Astrid A.M. van der Veldt, A. Becker-Commissaris, F. Terheggen, B.E.E.M. van den Borne, L.J.C. van Warmerdam, L. van Leeuwen, F.S. van der Meer, M.A. Tiemessen, D.M. van Diepen, L. Strobbe, J.A.F. Koekkoek, P. Brocken, J.C. Drooger, R. Heller, J.W.B. de Groot, J.A. Stigt, C.C.M. Pitz, M. Slingerland, F.J. Borm, B.C.M. Haberkorn, S.C. van 't Westeinde, M.J.B. Aarts, J.W.G. van Putten, M. Youssef, G.A. Cirkel, C.R. van Rooijen, E. Citgez, N.P. Barlo, B.M.J. Scholtes, R.H.T. Koornstra, N.J.M. Claessens, L.M. Faber, C.H. Rikers, R.A.W. van de Wetering, G.L. Veurink, B.W. Bouter, I. Houtenbos, M.P.L. Bard, G. Douma, M. Jalving, T.J.N. Hiltermann, O.C.J. Schuurbiers-Siebers, K.P.M. Suijkerbuijk, A.S.R. van Lindert, A.J. van de Wouw, V.E.M. van den Boogaart, S.D. Bakker, E. Looysen, W.K. de Jong, E.J.M. Siemerink, A.J. Staal, B. Franken, W.H. van Geffen

Publikováno v: European Journal of Cancer, 160, 261-272. ELSEVIER SCI LTD
European Journal of Cancer, 160, 261-272
European Journal of Cancer, 160, 261-272. Elsevier Ltd.
European Journal of Cancer, 160, pp. 261-272
European Journal of Cancer
European Journal of Cancer, 160, 261-272. Elsevier Limited

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment rest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a119f8d7c97e644ad36862f59fca45e
https://cris.maastrichtuniversity.nl/en/publications/e1ff4ef3-9b3a-4579-8518-3958ed43d2e9